QGEN
Qiagen N.V.
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$43.55
−0.71%Aug 27, 2026, 20:05 UTC
QIAGEN N.V. announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction, building on its QIAsymphony platform with over 3,300 cumulative placements worldwide.
Source:Aug 24, 2026, 13:56 UTC
Qiagen N.V. announced that Jonathan M. Pratt will become CEO on September 1, 2026, succeeding Thierry Bernard, who will step down but support the transition through the end of the year.
Aug 10, 2026, 20:05 UTC
QIAGEN announced that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
Source:Aug 6, 2026, 00:31 UTC
Qiagen reported its financial results for the quarter ended June 2026, with revenue and earnings compared to Wall Street estimates and year-ago values.
Aug 4, 2026, 06:45 UTC
QBY announced the acquisition of a 51% stake in GITG, an SAP healthcare specialist based in Hamburg, on the day before the publication date.
Source:Jul 14, 2026, 20:05 UTC
QIAGEN launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel for bloodstream infection testing in Europe.
Source:Jun 15, 2026, 05:30 UTC
QIAGEN N.V. launched new additions to its QIAcuity digital PCR ecosystem, expanding gene expression capabilities and assay content for life sciences and biopharma applications.
Source: